T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$7.49B |
| 2 |
Micron Technology
MU
|
+$6.62B |
| 3 |
Lam Research
LRCX
|
+$3.45B |
| 4 |
Applied Materials
AMAT
|
+$3.03B |
| 5 |
Advanced Micro Devices
AMD
|
+$2.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$12.1B |
| 2 |
Apple
AAPL
|
+$11.6B |
| 3 |
Amazon
AMZN
|
+$3.54B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.07B |
| 5 |
Keysight
KEYS
|
+$1.82B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.73% |
| 2 | Healthcare | 11.3% |
| 3 | Financials | 10.32% |
| 4 | Communication Services | 9.66% |
| 5 | Industrials | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RSVR
3076
Reservoir Media
RSVR
$584M
| $148K | ﹤0.01% |
14,956
| – | – |
|
3077
Protara Therapeutics
TARA
$226M
| $148K | ﹤0.01% |
38,483
+2,177
| +6% | +$10.4K |
|
3078
Barnes & Noble Education
BNED
$375M
| $147K | ﹤0.01% |
11,656
| – | – |
|
|
GEMI
3079
Gemini Space Station
GEMI
$577M
| $146K | ﹤0.01% |
+34,115
| New | +$161K |
|
3080
GoodRx Holdings
GDRX
$1.14B
| $145K | ﹤0.01% |
50,059
+11,627
| +30% | +$29.6K |
|
3081
Neumora Therapeutics
NMRA
$225M
| $144K | ﹤0.01% |
+84,155
| New | +$160K |
|
|
INR
3082
Infinity Natural Resources
INR
$284M
| $144K | ﹤0.01% |
11,295
+384
| +4% | +$5.71K |
|
3083
Medallion Financial
MFIN
$278M
| $143K | ﹤0.01% |
13,908
+788
| +6% | +$7.45K |
|
3084
Intellicheck
IDN
$53.7M
| $142K | ﹤0.01% |
34,602
+15,102
| +77% | +$90.5K |
|
3085
Orchestra BioMed
OBIO
$328M
| $142K | ﹤0.01% |
+32,689
| New | +$134K |
|
3086
Inspired Entertainment
INSE
$142M
| $140K | ﹤0.01% |
16,909
| – | – |
|
3087
SEACOR Marine Holdings
SMHI
$263M
| $140K | ﹤0.01% |
18,272
+5,508
| +43% | +$40.9K |
|
3088
Pixelworks
PXLW
$42.2M
| $139K | ﹤0.01% |
+22,284
| New | +$135K |
|
3089
SAB Biotherapeutics
SABS
$317M
| $139K | ﹤0.01% |
+35,620
| New | +$133K |
|
3090
American Vanguard Corp
AVD
$65.2M
| $138K | ﹤0.01% |
49,168
-2,375
| -5% | -$6.45K |
|
3091
TaskUs
TASK
$694M
| $138K | ﹤0.01% |
29,447
+1,240
| +4% | +$7.52K |
|
3092
Infosys
INFY
$44.3B
| $137K | ﹤0.01% |
+13,033
| New | +$163K |
|
3093
Health Catalyst
HCAT
$130M
| $136K | ﹤0.01% |
67,863
-31,347
| -32% | -$45.3K |
|
3094
Oramed Pharmaceuticals
ORMP
$199M
| $135K | ﹤0.01% |
+27,909
| New | +$111K |
|
3095
Crawford & Co Class A
CRD.A
$609M
| $134K | ﹤0.01% |
11,869
+586
| +5% | +$6.23K |
|
3096
Holley
HLLY
$353M
| $134K | ﹤0.01% |
52,363
| – | – |
|
3097
Organogenesis Holdings
ORGO
$202M
| $134K | ﹤0.01% |
54,876
+12,724
| +30% | +$31.1K |
|
|
FJET
3098
Starfighters Space Inc
FJET
$113M
| $134K | ﹤0.01% |
+25,184
| New | +$151K |
|
3099
Lucid Diagnostics
LUCD
$157M
| $131K | ﹤0.01% |
121,952
+47,575
| +64% | +$51.3K |
|
|
ONL
3100
Orion Office REIT
ONL
$149M
| $128K | ﹤0.01% |
+44,076
| New | +$121K |
|
Similar funds
T. Rowe Price Associates's Q2 2026 Portfolio in Review
As of Q2 2026, T. Rowe Price Associates held 3,356 positions worth $999B, up 16% from $865B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2026 filing shows 224 new, 2,237 increased, 645 reduced and 116 closed positions. Its largest new stake was SpaceX: 10,709,016 shares worth $1.83B. The largest sale was Microsoft, an estimated $12.1B.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2026 buy was SpaceX: 10,709,016 shares worth $1.83B.
- T. Rowe Price Associates added most to Alphabet (Google) Class A in Q2 2026, an estimated $7.49B increase.
- T. Rowe Price Associates's biggest Q2 2026 reduction was Microsoft, cutting an estimated $12.1B.
- T. Rowe Price Associates fully exited Sibanye-Stillwater in Q2 2026, selling an estimated $40.4M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $999B portfolio in Q2 2026.
- T. Rowe Price Associates opened 224 new positions and closed 116 in Q2 2026.
- T. Rowe Price Associates's portfolio value rose 16% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.